Yoshihiko Sakata

Kumamoto, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

Three versus six weeks of corticosteroids for mild immune-related pneumonitis: a randomized trial.

Journal: American journal of respiratory and critical care medicine

Published: January 25, 2026

Flare Reaction following Tarlatamab Treatment in a Patient with Extensive-Stage Small Cell Lung Cancer: Case Report.

Flare Reaction following Tarlatamab Treatment in a Patient with Extensive-Stage Small Cell Lung Cancer: Case Report.

Journal: Case reports in oncology

Published: September 23, 2025

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).

Atezolizumab with carboplatin plus nab-paclitaxel combination therapy for TTF-1 negative advanced nonsquamous non-small cell lung cancer: A multicenter, single-arm phase 2 trial (F1NE TUNE, LOGiK 2102).

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 06, 2025

Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer.

Impact of durvalumab re-administration after moderate symptomatic pneumonitis in locally advanced non-small cell lung cancer.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 30, 2025

Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.

Investigation of cardiotoxicity in patients treated with osimertinib: findings from the OSI-FACT study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 21, 2025

Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS).

Osimertinib as First-Line Treatment for Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer in a Real-World Setting: Updated Overall Survival Data (OSI-FACT-OS).

Journal: Clinical lung cancer

Published: January 01, 2025

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.

Long-term outcome of chemoimmunotherapy for extensive-stage small-cell lung cancer according to key clinical trial eligibility: 3-year outcomes from a prospective cohort study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 22, 2024

Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.

Durvalumab with etoposide and carboplatin for patients with extensive-stage small cell lung cancer and interstitial lung disease: A multicenter, open-label prospective trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: July 07, 2024

YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.

YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 04, 2024

Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy.

Inhibiting KRAS with CD47 and immune checkpoint overcomes intrinsic resistance to combined KRAS and immune checkpoint inhibitor therapy.

Journal: Cell reports. Medicine

Published: May 27, 2024

Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).

Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005).

Journal: Clinical lung cancer

Published: April 25, 2024

Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study.

Real-World Efficacy and Safety of Durvalumab Administration Following Chemoradiotherapy in Elderly Patients With Unresectable Locally Advanced Nonsmall Cell Lung Cancer: A Multicenter, Retrospective Study.

Journal: Clinical lung cancer

Published: February 18, 2024

Showing 1-12 of 30

Last Updated: 09/26/2026